Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17351371 | 0.90 | CES2 (0.40) | TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL391673 | 0.90 | RECQL (0.38) | TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL3495827 | 0.88 | CES2 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14946416 | 0.79 | CA2 (0.31) | — | |
| SCHEMBL16160349 | 0.77 | — | — | |
| SCHEMBL21100159 | 0.75 | MAPT (0.33) | ALDH1A1 | |
| SCHEMBL800709 | 0.75 | — | — | |
| SCHEMBL21099805 | 0.75 | MAPT (0.33) | ALDH1A1 | |
| SCHEMBL13197315 | 0.75 | MAPT (0.33) | ALDH1A1 | |
| SCHEMBL11714520 | 0.74 | CES2 (0.50) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441176-B1 | N-(5-CYCLOPROPYL-1-QUINOLIN-5-YL-1H-PYRAZOLE-4-CARBONYL) -GUANIDINE; REACTING QUINOLIN-5-YL-HYDRAZINE AND METHYL-3-CYCLOPROPYL-2-DIMETHYLENAMINO-3-OXOPROPANOATE, HYDROYLZING, FORMING ACYLHALIDE AND FURTHER REACTING WITH GUANIDINE | PFIZER INC. | 2002-08-27 | — | — | US | claimed |
| EP-1101763-A2 | Method for preparing sodium-hydrogen exchanger type 1 inhibitor | Pfizer Products Inc. (US) | 2001-05-23 | — | — | EP | claimed |
| US-20230400766-A1 | ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| CN-106986869-A | Compounds and methods for for antiviral therapy | 吉利德科学公司 | 2017-07-28 | — | — | CN | disclosed |
| EP-2298747-B1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2016-12-28 | — | — | EP | disclosed |
| CN-104583211-A | Compounds and methods for antiviral therapy | GILEAD SCIENCES INC | 2015-04-29 | — | — | CN | disclosed |
| CN-104327062-A | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INT | 2015-02-04 | — | — | CN | disclosed |
| EP-2708539-A1 | Annulated pyrimidines and triazines and their use | Bayer Intellectual Property GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| EP-2682394-A1 | 1H-pyrazolo[3,4-b]pyridin-triazine derivatives and their use for the treatment or the prevention of cardiovascular diseases | Bayer Intellectual Property GmbH (DE) | 2014-01-08 | — | — | EP | disclosed |
| EP-2590979-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-8202868-B2 | 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | MCMAHON GERALD (US) | 2002-05-30 | — | — | US | disclosed |
| EP-1012150-A4 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN INC (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6316479-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1101763-A2 | Method for preparing sodium-hydrogen exchanger type 1 inhibitor | Pfizer Products Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001030759-A2 | SODIUM-HYDROGEN EXCHANGER TYPE 1 INHIBITOR CRYSTALS | PFIZER PRODUCTS INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| EP-1012150-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | Sugen, Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998052944-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN, INC. (US) | 1998-11-26 | — | — | WO | disclosed |
| US-4588711-A | Insecticidal phosphorus derivatives of 6-cycloalkyl-4-pyrimidinols | THE DOW CHEMICAL COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4489068-A | Method and composition for enhancing the insecticidal activity of certain organophosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | TP53 862/4885SLC7A5 2748/4885ALDH1A1 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.